Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Will Wave Life Sciences maintain cash and equivalents above $400M at Q3 2026 quarter-end?
Current Prediction
Why This Question Matters
Cash runway is the binding constraint identified by the Stress Scanner. Quarterly cash balance below $400M without announced financing would signal compressed runway. This market tests whether the burn rate remains manageable or accelerates beyond guidance.
Prediction Distribution
Individual Predictions(9 runs)
Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Starting at $602M with Q3 2028 guided runway provides partial support, but r&d at $52.8m and rising creates counterweight. Probability: 0.6.
Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Starting at $602M with Q3 2028 guided runway provides partial support, but r&d at $52.8m and rising creates counterweight. Probability: 0.51.
Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Starting at $602M with Q3 2028 guided runway provides partial support, but r&d at $52.8m and rising creates counterweight. Probability: 0.56.
Base rate evidence: r&d at $52.8m and rising. Partial offset from starting at $602m with q3 2028 guided runway. Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Probability: 0.56.
Base rate evidence: r&d at $52.8m and rising. Partial offset from starting at $602m with q3 2028 guided runway. Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Probability: 0.61.
Base rate evidence: r&d at $52.8m and rising. Partial offset from starting at $602m with q3 2028 guided runway. Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Probability: 0.66.
Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Balance of evidence suggests 0.58 probability. Primary support: starting at $602m with q3 2028 guided runway. Main counterargument: r&d at $52.8m and rising.
Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Balance of evidence suggests 0.6 probability. Primary support: starting at $602m with q3 2028 guided runway. Main counterargument: r&d at $52.8m and rising.
Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Balance of evidence suggests 0.59 probability. Primary support: starting at $602m with q3 2028 guided runway. Main counterargument: r&d at $52.8m and rising.
Resolution Criteria
Resolves YES if Wave reports cash, cash equivalents, and short-term investments above $400M at Q3 2026 quarter-end. Resolves NO if below $400M.
Resolution Source
Wave Life Sciences Q3 2026 10-Q filing
Source Trigger
Cash balance at $602M (Q4 2025); below $400M without financing would signal compressed runway. R&D burn at $52.8M/quarter and accelerating
Full multi-lens equity analysis